Anti-Candida sp. (CAND-0869)

Anti-Candida sp. (CAND-0869)

Product No.: C012

- -
- -
Clone
CAND-0869
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Isotype
Rabbit IgG1
Applications
ELISA
,
IHC
,
IFA

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactivity Species
Candida sp.
Host Species
Rabbit
Product Concentration
≥1.0 mg/ml
Purity
≥90%
Formulation
Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
This monoclonal antibody is purified by protein A chromatography or sequential differential precipitations.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2-8°C Wet Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA: 1:20-1:200,
IFA: 1:10-1:50
Additional Applications Reported In Literature ?
IHC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Anti-Candida (Clone CAND-0869) is specific for several Candida species: C. albicans (10 strains), C. parapsillosis, C. glabrata, C. tropicales & C. auris. It is not reactive with C. krusei, Aspergillus, Coccidioides, Histoplasma, Blastomyces, Paracoccidioides, Penicillium notatum, Mucor, Saccharomyces cerevisiae, and Pichia pastoris.
Matched Pair
CAND-0869 pairs with itself in ELISA
Background
Candida species are opportunistic fungal pathogens commonly associated with healthcare-associated infections (HAIs), particularly in immunocompromised and critically ill patients. Candida infections, also known as candidiasis or yeast infections, can manifest as a variety of clinical syndromes, including bloodstream infections, urinary tract infections, surgical site infections, and candidemia. The most frequently isolated species in the context of HAIs are Candida albicans, followed by non-albicans species like Candida glabrata, Candida parapsilosis, and Candida tropicalis. Risk factors for Candida HAIs include the use of broad-spectrum antibiotics, central venous catheterization, prolonged hospitalization, and immunosuppressive therapies. Candida species have the ability to form biofilms on medical devices, further complicating treatment and facilitating their persistence in healthcare environments. Due to the rising incidence of multidrug-resistant Candida strains, early diagnosis, appropriate antifungal therapy, and infection control measures are critical to effectively manage Candida-related HAIs and improve patient outcomes.

Antigen Details

Research Area
Fungal
.
Infectious Disease
.
Matched Pair
.
Nosocomial
.
IVD Raw Material

References & Citations

Indirect Elisa Protocol
IHC
IFA

Formats Available

- -
- -
Prod No.
Description
C012
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.